Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension

European Respiratory Journal

Volumn 35, Issue 1, 2010, Pages 95-104

  Mathai, S C ^a   Bueso, M ^a   Hummers, L K ^a   Boyce, D ^a   Lechtzin, N ^a   Le Pavec, J ^a   Campo, A ^a   Champion, H C ^a   Housten, T ^a   Forfia, P R ^a   Zaiman, A L ^a   Wigley, F M ^a   Girgis, R E ^a   Hassoun, P M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prognostic markers; Pulmonary hypertension; Scleroderma

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; DIHYDROPYRIDINE DERIVATIVE; DIHYDROPYRIDINE TYPE CALCIUM CHANNEL BLOCKER; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NEUROHORMONE; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; HYPERTENSION; IDOPATHIC PULMONARY HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SURVIVAL; SYSTEMIC SCLEROSIS;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 75149119884     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00074309     Document Type: Article

References (61)

1. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-3800.
2. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum 2005; 52: 2125-2132.
3. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-1192.
4. Kawut SM, Taichman DB, Archer-Chicko CL, et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest 2003; 123: 344-350.
5. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum 2006; 54: 3043-3050.
6. Kahan A, Devaux JY, Amor B, et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986; 314: 1397-1402.
7. Fernandes F, Ramires FJ, Arteaga E, et al. Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003; 9: 311-317.
8. de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67: 31-36.
9. Tongers J, Schwerdtfeger B, Klein G, et al. Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 2007; 153: 127-132.
10. Castelain V, Herve P, Lecarpentier Y, et al. Pulmonary artery pulse pressure and wave reflection in chronic pulmonary thrombo-embolism and primary pulmonary hypertension. J Am Coll Cardiol 2001; 37: 1085-1092.
11. Forfia PR, Mathai SC, Fisher MR, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 177: 1364-1369.
12. Mathai SC, Forfia PR, Girgis RE, et al. Plasma catecholamine levels differ between idiopathic and scleroderma-related pulmonary arterial hypertension. Proc Am Thorac Soc, 2008: A444.
13. Williams MH, Handler CE, Akram R, et al. Role of N-terminal brain natriuretic peptide (NT-proBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494.
14. Fijalkowska A, Kurzyna M, Torbicki A, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006; 129: 1313-1321.
15. Simonneau G, Fartoukh M, Sitbon O, et al. Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 1998; 114: 195S-199S.
16. Tuder RM, Radisavljevic Z, Shroyer KR, et al. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med 1998; 158: 1999-2001.
17. LeRoy EC, Black C, Fleischemajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202-205.
18. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 40S-47S.
19. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43: 5S-12S.
20. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659-664.
21. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123: 185-189.
22. Crapo RO, Morris AH, Clayton PD, et al. Lung volumes in healthy nonsmoking adults. Bull Eur Physiopathol Respir 1982; 18: 419-425.
23. MacDonald SL, Rubens MB, Hansell DM, et al. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CT. Radiology 2001; 221: 600-605.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
25. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSYM and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta 2006; 369: 95-99.
26. Souza R, Jardim C, Fernandes CJC, et al. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 2007; 101: 69-75.
27. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29: 737-744.
28. van Wolferen SA, Boonstra A, Marcus JT, et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006; 92: 1860-1861.
29. Souza R, Jardim C, Martins B, et al. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005; 21: 907-911.
30. Dimitroulas T, Giannakoulas G, Karvounis H, et al. N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol 2008; 27: 655-658.
31. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006; 28: 1190-1194.
32. Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007; 131: 402-409.
33. Mukerjee D, Yap LB, Holmes AM, et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97: 1230-1236.
34. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40: 976-982.
35. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163-2168.
36. Overbeek MJ, Lankhaar JW, Westerhof N, et al. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. Eur Respir J 2008; 31: 1160-1166.
37. Forfia PR, Fisher MR, Mathai SC, et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1034-1041.
38. Wung PK, Wigley FM, Hummers LK, et al. Myocardial fibrosis and inflammation in scleroderma: histopathologic analysis. Arthritis Rheum 2008; 58: S376-S377.
39. Tsuruda T, Boerrigter G, Huntley BK, et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002; 91: 1127-1134.
40. Vanderheyden M, Goethals M, Verstreken S, et al. Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol 2004; 44: 2349-2354.
41. Weber KT, Janicki JS. Myocardial oxygen consumption: the role of wall force and shortening. Am J Physiol 1977; 233: H421-H430.
42. Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000; 59: 94-98.
43. Lindqvist P, Caidahl K, Neuman-Andersen G, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest 2005; 128: 755-763.
44. Huez S, Roufosse F, Vachiery JL, et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J 2007; 30: 928-936.
45. Gan CT, Holverde S, Marcus JT, et al. Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest 2007; 132: 11-17.
46. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
47. Klimiuk PS, Taylor L, Baker RD, et al. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 1988; 47: 542-545.
48. Zakrzewska-Pniewska B, Jablonska S, Kowalska-Oledzka E, et al. Sympathetic skin response in scleroderma, scleroderma overlap syndromes and inflammatory myopathies. Clin Rheumatol 1999; 18: 473-480.
49. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 569-575.
50. Roberts CG, Hummers LK, Ravich WJ, et al. A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma). Gut 2006; 55: 1697-1703.
51. Harada M, Saito Y, Kuwahara K, et al. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J Cardiovasc Pharmacol 1998; 31: Suppl. 1, S357-S359.
52. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 2003; 65: 81-101.
53. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-823.
54. Langleben D, Dupuis J, Langleben I, et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006; 129: 689-695.
55. Hopkins WE, Chen Z, Fukagawa NK, et al. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004; 109: 2872-2877.
56. Due-Andersen R, Pedersen-Bjergaard U, Hoi-Hansen T, et al. NTpro-BNP during hypoglycemia and hypoxemia in normal subjects: impact of renin-angiotensin system activity. J Appl Physiol 2008; 104: 1080-1085.
57. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 2009; 60: 569-577.
58. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue diseaseassociated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-157.
59. Mathai SC, Hassoun PM. N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2007; 28: 140-141.
60. Allanore Y, Borderie D, Meune C, et al. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary arterial hypertension in patients with systemic sclerosis and effects of calcium channel blockers. Arthritis Rheum 2003; 48: 3503-3508.
61. Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360-365.